WNK2 and melanoma: The introduction of BRAF inhibitors marked a significant advancement in the management of advanced melanoma, highlighting the critical role of the BRAF and MEK proteins in melanoma pathogenesis through their involvement in the mitogen-activated protein kinase (MAPK) pathway [21].